Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Prostate Cancer
Optimizing Care and Managing Side Effects in Prostate Cancer
Clinicians need up-to-date information on when and how to use molecular assays to inform individual patient risk, so that men with localized prostate cancer can receive optimal treatment while avoiding unnecessary treatment and side effects. In addition, clinicians must be knowledgeable about the side effects of androgen deprivation therapy (ADT) and management options for these side effects. Finally, clinicians must be aware of results of recent clinical trials in the non-metastatic castration-resistant prostate cancer (CRPC) setting, so that patients can receive optimal care and delay the onset of metastases as long as possible.
This educational program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with cancer.
Following this activity, participants should be able to:
- Identify patients with localized prostate cancer for whom molecular profiling may inform treatment decisions.
- Recognize and manage the side effects of androgen deprivation therapy (ADT).
- Apply the results of recent clinical trials in the non-metastatic castration-resistant prostate cancer (CRPC) setting to optimize patient care.
Edward Schaeffer, MD, PhD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Alicia K. Morgans, MD, MPH
Northwestern University Feinberg School of Medicine
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics).
Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.
NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
The faculty listed below discloses the following relevant financial relationships:
Alicia K. Morgans, MD, MPH
Advanced Accelerator Applications: Consulting Fee
Astellas Pharma US, Inc.: Consulting Fee
AstraZeneca Pharmaceuticals LP: Consulting Fee
Bayer HealthCare: Consulting Fee; Grant/Research Support
Janssen Pharmaceutica Products, LP: Consulting Fee
Myovant Sciences Ltd.: Consulting Fee
sanofi-aventis U.S.: Consulting Fee
Edward Schaeffer, MD, PhD
AbbVie, Inc.: Scientific Advisor
Janssen Scientific Affairs, LLC: Scientific Advisor
NCCN Staff Disclosures
The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Perfidio, MS; Shannon Ryan, CMP; Kathy Ann Smith, CHCP; Sarah Weinstein
The NCCN Clinical staff listed below discloses no relevant financial relationships:
Deborah Freedman-Cass, PhD
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 1.0 contact hour.
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-20-073-L01-P
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 0.75 CE contact hour. Activity Code: I00042797; Approval #: 200137711
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 CCM clock hours
- 1.00 Participation
This webinar was presented live one time only on Friday, July 31, 2020, from 1:30 - 2:30 PM EDT (UTC -4).
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing